← Hyperscale Data overview

Hyperscale Data vs Zhejiang Jianfeng: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hyperscale Data, Inc. (GPUS)

Q3 2026
▲3▼1

Hyperscale Data pivots from Bitcoin mining to AI data centers with $1.2B+ deal

  • Signs $1.2B AI compute deal, potential $3B+ Hyperscale Data signed a long-term contract to provide AI computing space to a California cloud provider. The deal starts at 20 megawatts and could grow to 52 megawatts, generating over $1.2 billion in revenue, or more than $3 billion if fully expanded. This new business is the main reason the stock is moving.

    This is the core new event that transforms the company's business and drives the stock.

  • $300M at-the-market equity offering dilutes shareholders The company launched a program to sell up to $300 million in new shares. This increases the number of shares outstanding, which typically lowers the value of each existing share. The money will fund data centers and buy Bitcoin, but the dilution is a real drag on the stock price.

    This is a major new financing event that directly impacts share count and investor value.

  • Bitcoin treasury surpasses 1,000 BTC, then sells 100 to fund AI campus Hyperscale Data built a Bitcoin treasury above 1,000 coins, giving it a valuable asset that can be used as collateral. It then sold about 100 Bitcoin to fund construction of its Michigan AI data center and secured a credit line against the rest. This shows the company is using its crypto holdings to support the AI pivot without relying only on new share sales.

    This shows how the company is funding its AI expansion and managing its balance sheet, which affects investor confidence.

  • Halts Michigan Bitcoin mining to make room for AI infrastructure The company stopped all Bitcoin mining at its Michigan data center to prepare the site for its new AI customer. This is a concrete step that shows the $1.2 billion deal is moving forward. It also means the company is fully committing to AI over crypto mining, which could lead to more stable, long-term revenue.

    This is a new operational milestone that confirms the AI deal is being implemented, supporting the stock.

July 2026
▲3▼1

Hyperscale Data pivots from Bitcoin mining to AI data centers with $1.2B+ deal

  • Signs $1.2B AI compute deal, potential $3B+ Hyperscale Data signed a long-term contract to provide AI computing space to a California cloud provider. The deal starts at 20 megawatts and could grow to 52 megawatts, generating over $1.2 billion in revenue, or more than $3 billion if fully expanded. This new business is the main reason the stock is moving.

    This is the core new event that transforms the company's business and drives the stock.

  • $300M at-the-market equity offering dilutes shareholders The company launched a program to sell up to $300 million in new shares. This increases the number of shares outstanding, which typically lowers the value of each existing share. The money will fund data centers and buy Bitcoin, but the dilution is a real drag on the stock price.

    This is a major new financing event that directly impacts share count and investor value.

  • Bitcoin treasury surpasses 1,000 BTC, then sells 100 to fund AI campus Hyperscale Data built a Bitcoin treasury above 1,000 coins, giving it a valuable asset that can be used as collateral. It then sold about 100 Bitcoin to fund construction of its Michigan AI data center and secured a credit line against the rest. This shows the company is using its crypto holdings to support the AI pivot without relying only on new share sales.

    This shows how the company is funding its AI expansion and managing its balance sheet, which affects investor confidence.

  • Halts Michigan Bitcoin mining to make room for AI infrastructure The company stopped all Bitcoin mining at its Michigan data center to prepare the site for its new AI customer. This is a concrete step that shows the $1.2 billion deal is moving forward. It also means the company is fully committing to AI over crypto mining, which could lead to more stable, long-term revenue.

    This is a new operational milestone that confirms the AI deal is being implemented, supporting the stock.

Latest
▲3▼1

Hyperscale Data pivots from Bitcoin mining to AI data centers with $1.2B+ deal

  • Signs $1.2B AI compute deal, potential $3B+ Hyperscale Data signed a long-term contract to provide AI computing space to a California cloud provider. The deal starts at 20 megawatts and could grow to 52 megawatts, generating over $1.2 billion in revenue, or more than $3 billion if fully expanded. This new business is the main reason the stock is moving.

    This is the core new event that transforms the company's business and drives the stock.

  • $300M at-the-market equity offering dilutes shareholders The company launched a program to sell up to $300 million in new shares. This increases the number of shares outstanding, which typically lowers the value of each existing share. The money will fund data centers and buy Bitcoin, but the dilution is a real drag on the stock price.

    This is a major new financing event that directly impacts share count and investor value.

  • Bitcoin treasury surpasses 1,000 BTC, then sells 100 to fund AI campus Hyperscale Data built a Bitcoin treasury above 1,000 coins, giving it a valuable asset that can be used as collateral. It then sold about 100 Bitcoin to fund construction of its Michigan AI data center and secured a credit line against the rest. This shows the company is using its crypto holdings to support the AI pivot without relying only on new share sales.

    This shows how the company is funding its AI expansion and managing its balance sheet, which affects investor confidence.

  • Halts Michigan Bitcoin mining to make room for AI infrastructure The company stopped all Bitcoin mining at its Michigan data center to prepare the site for its new AI customer. This is a concrete step that shows the $1.2 billion deal is moving forward. It also means the company is fully committing to AI over crypto mining, which could lead to more stable, long-term revenue.

    This is a new operational milestone that confirms the AI deal is being implemented, supporting the stock.

Zhejiang Jianfeng Group Co Ltd (600668.CG)

Q3 2026
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.

August 2026
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.

Latest
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.